search
Back to results

A Shared Decision Making Intervention for Diabetes Prevention in Women With a History of Gestational Diabetes Mellitus

Primary Purpose

Gestational Diabetes Mellitus, Pre-diabetes, Diabetes Mellitus, Type 2

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Shared decision-making for diabetes prevention
Sponsored by
University of California, Los Angeles
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Gestational Diabetes Mellitus focused on measuring Diabetes Prevention, Shared Decision Making

Eligibility Criteria

18 Years - 54 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • BMI 25 kg/m2 or above (23 or above if Asian American woman)
  • History of gestational diabetes mellitus
  • History of prediabetes in prior 36 months defined by either 1) most recent HbA1c 5.7-6.4% or 2) most recent FPG 100-125 mg/dL or 3) prior diabetes diagnostic codes + abnormal labs
  • Patient at UCLA or Intermountain Healthcare Systems with provider visit or labs in prior 12 months

Exclusion Criteria:

  • Delivery within prior 12 months
  • History of diabetes (i.e., prior HbA1c 6.5% or above, or 2 or more fasting plasma glucose 125 or above, or prior diagnostic code)
  • Use of an anti-glycemic medication in prior 12 months
  • Last available glomerular filtration rate (eGFR) <45 ml/min
  • BMI >60 kg/m2
  • Bariatric surgery with prior 12 months
  • Active eating disorder
  • Currently pregnant or planning to get pregnant in the next 12-24 months
  • Currently breastfeeding
  • Completed a prediabetes SDM consult in past
  • Currently enrolled in a CDC recognized Diabetes Prevention Program (DPP)
  • Inability or concerns about doing >150 minutes of physical activity per week
  • History of metformin intolerance
  • Non-English primary language

Sites / Locations

  • University of California, Los AngelesRecruiting
  • Intermountain Healthcare SystemRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Shared decision-making with pharmacists

Usual Care

Arm Description

Participants randomized to the intervention arm will have an in-person visit to complete the baseline survey, record the participant's weight and receive a pharmacist-coordinated shared decision making intervention. Intervention participants will have follow-up research assessments visits at 6, 12 and 24 months.

Participants randomized to the usual care control arm will have an in-person visit with the research study team to complete the baseline survey and record the participant's weight. These participants will then return to usual care with research assessments at 6, 12 and 24 months follow-up.

Outcomes

Primary Outcome Measures

Weight change
Proportion with >5% weight loss

Secondary Outcome Measures

Weight Change
Proportion with >5% weight loss
Uptake of DPP lifestyle program or metformin
1) Attending at least 9 of 16 of weekly lifestyle change sessions OR 2) Taking metformin (yes/no)
Health-related quality of life
Short-form (SF-36) measure

Full Information

First Posted
May 18, 2021
Last Updated
October 10, 2023
Sponsor
University of California, Los Angeles
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Intermountain Health Care, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04897945
Brief Title
A Shared Decision Making Intervention for Diabetes Prevention in Women With a History of Gestational Diabetes Mellitus
Official Title
A Shared Decision Making Intervention for Diabetes Prevention in Women With a History of Gestational Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 12, 2021 (Actual)
Primary Completion Date
March 31, 2025 (Anticipated)
Study Completion Date
October 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Los Angeles
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Intermountain Health Care, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Our goal is to test whether shared decision making for diabetes prevention can help women with a history of gestational diabetes mellitus (GDM) who are at high risk of developing type 2 diabetes (T2DM) increase weight loss and adoption of evidence based strategies to lower their risk of incident diabetes.
Detailed Description
Women with a history of gestational diabetes mellitus (GDM) are at high risk of developing type 2 diabetes (T2DM) but evidence from the Diabetes Prevention Program (DPP) indicates that lifestyle change and metformin use in this population are clinically equivalent, each reducing the incidence of T2DM by approximately 50%. Shared decision making (SDM) is an attractive approach in this situation where several options are available. We can use a decision aid to make the decision explicit, describe the available options with equipoise, elicit patient preferences, and help patients make an informed decision that is right for them. There are no existing studies evaluating SDM for diabetes prevention among women with a history of GDM. Therefore, this study aims to test the effectiveness of an RCT evaluating SDM for diabetes prevention on weight loss among overweight/obese women with a history of GDM and hemoglobin A1c between 5.7-6.4%, as well as uptake of lifestyle change and/or metformin use and other patient-reported outcomes (e.g., physical activity, eating patterns, patient activation, health-related quality of life). The study will recruit 310 patients from two large health care systems (n=155 from UCLA Health and n=155 from Intermountain Healthcare) who will be randomized to either usual care or in-person shared decision making for diabetes prevention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes Mellitus, Pre-diabetes, Diabetes Mellitus, Type 2
Keywords
Diabetes Prevention, Shared Decision Making

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
310 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Shared decision-making with pharmacists
Arm Type
Experimental
Arm Description
Participants randomized to the intervention arm will have an in-person visit to complete the baseline survey, record the participant's weight and receive a pharmacist-coordinated shared decision making intervention. Intervention participants will have follow-up research assessments visits at 6, 12 and 24 months.
Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
Participants randomized to the usual care control arm will have an in-person visit with the research study team to complete the baseline survey and record the participant's weight. These participants will then return to usual care with research assessments at 6, 12 and 24 months follow-up.
Intervention Type
Behavioral
Intervention Name(s)
Shared decision-making for diabetes prevention
Intervention Description
Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
Primary Outcome Measure Information:
Title
Weight change
Description
Proportion with >5% weight loss
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Weight Change
Description
Proportion with >5% weight loss
Time Frame
24 months
Title
Uptake of DPP lifestyle program or metformin
Description
1) Attending at least 9 of 16 of weekly lifestyle change sessions OR 2) Taking metformin (yes/no)
Time Frame
6 months
Title
Health-related quality of life
Description
Short-form (SF-36) measure
Time Frame
6, 12, and 24 months

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
54 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: BMI 25 kg/m2 or above (23 or above if Asian American woman) History of gestational diabetes mellitus History of prediabetes in prior 36 months defined by either 1) most recent HbA1c 5.7-6.4% or 2) most recent FPG 100-125 mg/dL or 3) prior diabetes diagnostic codes + abnormal labs Patient at UCLA or Intermountain Healthcare Systems with provider visit or labs in prior 12 months Exclusion Criteria: Delivery within prior 12 months History of diabetes (i.e., prior HbA1c 6.5% or above, or 2 or more fasting plasma glucose 125 or above, or prior diagnostic code) Use of an anti-glycemic medication in prior 12 months Last available glomerular filtration rate (eGFR) <45 ml/min BMI >60 kg/m2 Bariatric surgery with prior 12 months Active eating disorder Currently pregnant or planning to get pregnant in the next 12-24 months Completed a prediabetes SDM consult in past Currently enrolled in a CDC recognized Diabetes Prevention Program (DPP) Inability or concerns about doing >150 minutes of physical activity per week History of metformin intolerance Non-English primary language
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Richard Maranon
Phone
310-206-4177
Email
rmaranon@mednet.ucla.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kenrik Duru, MD,MSHS
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tannaz Moin, MD,MBA,MSHS
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90024
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kenrik Duru, MD,MSHS
First Name & Middle Initial & Last Name & Degree
Tannaz Moin, MD,MBA,MSHS
Facility Name
Intermountain Healthcare System
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kim Brunisholz, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Shared Decision Making Intervention for Diabetes Prevention in Women With a History of Gestational Diabetes Mellitus

We'll reach out to this number within 24 hrs